Raptor Pharma Gets IP License For Huntington Disease Treatment
The Weizmann and Niigata patents cover the use of transglutaminase inhibitors, a class of molecules chemically similar to Cysteamine, in the potential treatment of Huntington’s Disease and other
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.